News
-
According to Invion Limited, the company “has received a positive response” from the FDA during a pre-IND meeting regarding its INV102 inhaled nadolol for the treatment of asthma and COPD. Invion is developing the drug… Read more . . .
-
Verona Pharma has announced what it calls “encouraging interim results” from a Phase 1/2 study of a new formulation of its RPL554 PDE3/4 inhibitor for the treatment of COPD exacerbations. The company had announced the… Read more . . .
-
Arikayce inhaled liposomal amikacin developer Insmed Incorporated has announced the appointment of Eugene Sullivan, a former FDA Deputy Director of the Division of Pulmonary and Allergy Products, as Chief Medical and Scientific Officer. Sullivan has… Read more . . .
-
A public/private partnership in Louisville, Kentucky called AIR Louisville will distribute 2,000 Propeller Health inhaler sensors to asthma patients across the city as part of a 2-year data collection program, according to Propeller. The FDA… Read more . . .
-
The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) and Drug Safety and Risk Management Advisory Committee have voted 16-4 to recommend the approval of GSK’s Breo Ellipta fluticasone/vilanterol DPI for the treatment of asthma in patients… Read more . . .
-
AstraZeneca has announced that data from two Phase 3 studies of its PT003 glycopyrronium/formoterol MDI for the treatment of COPD showed statistically significant improvements in lung function for patients using PT003 compared to each of… Read more . . .
-
Discovery Laboratories has announced that it will switch its focus from Surfaxin lucinactant intratracheal suspension product to development of its Aerosurf aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants. The… Read more . . .
-
In a letter from the FDA to Sunovion dated March 12, 2015, the agency informed the company that all postmarketing requirements and commitments specified after the 2005 approval of the Xopenex HFA levalbuterol MDI have… Read more . . .
-
The FDA has listed PARI’s Kitabis Pak in the Orange Book as a therapeutic equivalent of Novartis’s TOBI tobramycin inhalation solution with an AN rating, PARI has announced. Kitabis Pak, tobramycin inhalation solution packaged with… Read more . . .
-
California-based biopharmaceutical company Ruthigen and inhaled drug developer Pulmatrix have announced a definitive merger agreement under whose terms Pulmatrix will become a wholly-owned subsidiary of Ruthigen. According to the announcement, conversion of Pulmatrix’s outstanding debt… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA